Efficacies of ABT-773, a new ketolide, against experimental bacterial infections

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 9, 2001, Pages 2585-2593

  Mitten, M J ^a   Meulbroek, J ^a   Nukkala, M ^a   Paige, L ^a   Jarvis, K ^a   Oleksijew, A ^a   Tovcimak, A ^a   Hernandez, L ^a   Alder, J D ^a   Ewing, P ^a   Or, Y S ^a   Ma, Z ^a   Nilius, A M ^a   Mollison, K ^a   Flamm, R K ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CETHROMYCIN; CLARITHROMYCIN; KETOLIDE; PENICILLIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HAEMOPHILUS INFLUENZAE; LISTERIA MONOCYTOGENES; LISTERIOSIS; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANIMALS; BACTERIAL INFECTIONS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MICROBIAL; ERYTHROMYCIN; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; KETOLIDES; LISTERIA INFECTIONS; LUNG DISEASES; MALE; MICE; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATORY TRACT DISEASES; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 17944377202     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.9.2585-2593.2001     Document Type: Article

References (36)

1. Antibacterial activity of RU 64004 (HMR 3004), a novel ketolide derivative active against respiratory pathogens
2. Comparative chemotherapeutic activity of temafloxacin, cefoxitin, clindamycin, imipenem and ampicillin/sulbactam against Bacteroides fragilis in a mouse subcutaneous abscess model
3. Efficacies of ABT-719 and related 2-pyridone, members of a new class of antibacterial agents, against experimental bacterial infections
4. Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection
5. In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae
6. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial drugs (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains
7. Emergence of drug-resistance pneumococcal infections in the United States
8. In vivo activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus infiuenzae, and Moraxella catarrhalis
9. Studies of the novel ketolide ABT-773: Transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae
10. Recent developments in macrolides and ketolides
11. Influence of increased macrolide consumption on macrolide resistance of common respiratory pathogens
12. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone
13. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin
14. Prevalence and mechanism of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada
15. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-1998
16. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of β-lactamase-positive strains resistant to amoxicillin-clavulanate: Results of a national multicenter surveillance study
17. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study
18. Treatment of experimental pneumonia due to penicillin-resistant Streptococcus pneumoniae in immunocompetent rats
19. Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones
20. Prevalence and characterization of mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae
21. Macrolide resistance mechanisms and expression of phenotypes among Streptococcus pneumonia circulating in Italy
22. Pharmacokinetics and pharmacodynamics of newer macrolides
23. Comparative in vitro activity of ABT-773, a novel antibacterial ketolide
24. Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against respiratory tract pathogens
25. Patterns of macrolide resistance determinants among community-acquired Streptococcus pneumoniae isolates over a 5-year period of decreased macrolide susceptibility rates
26. Ketolide treatment of Haemophilus influenzae experimental pneumonia
27. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers
28. Distribution of serotypes and antimicrobial resistance of Streptococcus pneumoniae strains isolated in Brazil from 1988 to 1992
29. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995
30. Maintaining standards: Differences between the standard deviation and standard error, and when to use each
31. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season
32. Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: Results of a Canadian national surveillance study
33. Induction of ribosome methylation in MLS-resistant Streptococcus pneumoniae by macrolides and ketolides
34. The newer macrolides azithromycin and clarithromycin